University of Minnesota Medical Center, 516 S=Delaware St SE
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mazepa, Marshall
NCT05695391: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting
3
19
US, RoW
Coagulation Factor VIIa (Recombinant)
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
06/25
07/25
VAYHIA, NCT05648968: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Recruiting
3
90
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
03/26
02/29
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting
2
40
Europe, US, RoW
TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Takeda, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
03/25
03/25

Download Options